Discovery of MAO-B inhibitors - present status and future directions part I: Oxygen heterocycles and analogs

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 907-919

  Helguera, A M ^a,b   Perez Machado G ^b   Cordeiro, M N D S ^a   Borges, F ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b CENTRAL UNIVERSITY OF LAS VILLAS   (Cuba)

Author keywords

Chalcones; Chromones; Coumarins; MAO inhibitors; Multi target; Parkinson's disease; SAR

Indexed keywords

7 (3,4 DIFLUOROBENZYLOXY) 3,4 DIMETHYLCOUMARIN; 7 (BENZYLOXY) 3,4 DIMETHYLCOUMARIN DERIVATIVE; ACETYLCHOLINESTERASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AROMATASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHALCONE DERIVATIVE; CHROMONE DERIVATIVE; CLORGYLINE; COUMARIN 3 ACYL CHLORIDE DERIVATIVE; COUMARIN 3 CARBOXYLIC ACID; COUMARIN DERIVATIVE; DOPAMINE; HETEROCYCLIC COMPOUND; LADOSTIGIL; LEVODOPA; MOCLOBEMIDE; MONOAMINE OXIDASE B INHIBITOR; NW 1772; RASAGILINE; RIVASTIGMINE; SAFINAMIDE; SELEGILINE; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE;

ADJUVANT THERAPY; DEPRESSION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; IC 50; NONHUMAN; PALLIATIVE THERAPY; PARKINSON DISEASE; REVIEW; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; CHALCONES; CHROMONES; COUMARINS; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE;

EID: 84866449811     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712802762301     Document Type: Review

References (84)

1. Edmondson, D.E.; Binda, C.; Mattevi, A. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch Biochem Biophys, 2007, 464, (2), 269-276.
2. Elmer, L.W.; Bertoni, J.M. The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy. Expert Opin Pharmacother, 2008, 9, (16), 2759-2772.
3. Edmondson, D.E.; Bhattacharyya, A.K.; Walker, M.C. Spectral and kinetic studies of imine product formation in the oxidation of p- (N,N-dimethylamino)-benzylamine analogs by monoamine oxidase B. Biochemistry, 1993, 32, 5196-5202.
4. Bortolato, M.; Chen, K.; Shih, J.C. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev, 2008, 60, (13/14), 1527-1533.
5. Chen, J.J.; Swope, D.M.; Dashtipour, K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther, 2007, 29, (9), 1825-1849.
6. Youdim, M.B.; Edmondson, D.; Tipton, K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci, 2006, 7, (4), 295-309.
7. Chen, J.J.; Swope, D.M. Pharmacotherapy for Parkinson's disease. Pharmacotherapy, 2007, 27, (12 Pt 2), 161S-173S.
8. Burke, W.J.; Kumar, V.B.; Pandey, N.; Panneton, W.M.; Gan, Q.; Franko, M.W.; O'Dell, M.; Li, S.W.; Pan, Y.; Chung, H.D.; Galvin, J.E. Aggregation of R-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol., 2008, 115, 193-203.
9. Mallajosyula, J.K.; Kaur, D.; Chinta, S.J.; Rajagopalan, S.; Rane, A.; Nicholls, D.G.; Di Monte, D.A.; Macarthur, H.; Andersen, J.K. MAO B elevation in mouse brain astrocytes results in Parkinson's pathology. PloS One, 2008, 3, e1616.
10. Fowler, J.S.; Logan, J.; Volkow, N.D.; Wang, G.J.; MacGregor, R.R.; Ding, Y.S. Monoamine oxidase: Radiotracer development and human studies. Methods, 2002, 27, 263-277.
11. Kumar, M.J.; Nicholls, D.G.; Andersen, J.K. Oxidative alphaketoglutarate dehydrogenase inhibition via subtle elevations in monoamine oxidase B levels results in loss of spare respiratory capacity: implications for Parkinson's disease. J Biol Chem, 2003, 278, (47), 46432-46439.
12. Schapira, A.H. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology, 2009, 72, (7 Suppl), S44-50.
13. Tipton, K.F.; Strolin-Benedetti, M. Enzyme systems that metabolise drugs and other xenobiotics. John Wiley & Sons: Chichester, UK, 2001.
14. Factor, S.A. Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics, 2008, 5, (2), 164-180.
15. Knoll, J. (-)Deprenyl (Selegiline): past, present and future. Neurobiology (Bp.), 2000, 8, 179-199.
16. Youdim, M.B.; Edmondson, D.E.; Tipton, K.F. The Therapeutic Potential of Monoamine Oxidase Inhibitors. Nat. Rev. Neurosci., 2006, 7, 295-309.
17. Olanow, C.W. Rationale for Considering that Propargylamines Might Be Neuroprotective in Parkinson's Disease. Neurology, 2006, 66, S69-S79.
18. Olanow, C.W. Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Neurology, 2009, 72, (7 Suppl), S59-64.
19. Olanow, C.W.; Kieburtz, K.; Schapira, A.H. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol, 2008, 64 Suppl 2, S101-110.
20. Schapira, A.H.; Olanow, C.W. Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol, 2008, 64 Suppl 2, S47-S55.
21. Jost, W.H.; Klasser, M.; Reichmann, H. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. Fortschr Neurol Psychiatr, 2008, 76, (10), 594-599.
22. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M.B. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol, 2010, 92, (3), 330-344.
23. Bar-Am, O.; Weinreb, O.; Amit, T.; Youdim, M.B. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem, 2010, 112, (5), 1131-1137.
24. Reyes-Parada, M.; Fierro, A.; Iturriaga-Vásquez, P.; Cassels, B.K. Monoamine Oxidase Inhibition In the Light of New Structural Data. Current Enzyme Inhibition, 2005, 1, 85-95.
25. Yamada, M.; Yasuhara, H. Clinical Pharmacology of MAO Inhibitors: Safety and Future. Neurotoxicol., 2004, 25, 215-221.
26. Edmondson, D.E.; Binda, C.; Wang, J.; Upadhyay, A.K.; Mattevi, A. Molecular and Mechanistic Properties of the Membrane-Bound Mitochondrial Monoamine Oxidases. Biochemistry, 2009, 48(20), 4220-4230.
27. Youdim, M.B. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res, 2006, 3, (5), 541-550.
28. Guay, D.R. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother, 2006, 4, (4), 330-346.
29. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Cirilli, R.; La Torre, F.; Alcaro, S.; Ortuso, F.; Langer, T. Synthesis, Biological Evaluation and 3DQSAR of 1,3,5-Trisubstituted-4,5-Dihydro-(1H)-Pyrazole derivatives as Potent and Highly Selective Monoamine Oxidase A Inhibitors. Current Medicinal Chemistry, 2006, 13, 1411-1428.
30. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of Monoamine Oxidases by Functionalized Coumarin Derivatives: Biological Activities, QSARs, and 3D-QSARs. J. Med. Chem., 2000, 43, 4747-4758.
31. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Chimenti, P.; Secci, D.; Rossi, F.; Yáñez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. Chalcones: A Valid Scaffold for Monoamine Oxidases Inhibitors. J. Med. Chem., 2009, 52, 2818-2824.
32. Matos, M.J.; Vina, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett, 2009, 19, (17), 5053-5055.
33. Matos, M.J.; Viña, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.; Uriarte, E. A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett, 2009, 19, (12), 3268-3270.
34. Alcaro, S.; Gaspar, A.; Ortuso, F.; Milhazes, N.; Orallo, F.; Uriarte, E.; Yáñez, M.; Borges, F. Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B. Bioorg Med Chem Lett, 2010, 20, 2709-2712.
35. Pisani, L.; Muncipinto, G.; Miscioscia, T.F.; Nicolotti, O.; Leonetti, F.; Catto, M.; Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; Passeleu, C.; Carotti, A. Discovery of a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one Methanesulfonate (NW-1772) as a Highly Potent, Selective, Reversible, and Orally Active Monoamine Oxidase B Inhibitor. J. Med. Chem., 2009, 52, (21), 6685-6706.
36. Pisani, L.; Muncipinto, G.; Miscioscia, T.; Nicolott, I.O.; Leonetti, F.; Catto, M.; Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; Passeleu, C.; Carotti, A. Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4- [(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor. J Med Chem., 2009, 52(21). 6685-6706.
37. Thull, U.; Kneubühler, S.; Testa, B.; Borges, M.F.M.; Pinto, M.M.M. Substituted xanthones as selective and reversible monoamine oxidase A (MAO-A) inhibitors. Pharm. Res, 1993, 10, (8), 1187-1190.
38. Deeb, O.; Alfalah, S.; Clare, B.W. QSAR of aromatic substances: MAO inhibitory activity of xanthone derivatives. J. Enzym. Inhib. Med. Chem., 2007, 22, (3), 277-286.
39. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F. Inhibition of monoamine oxidases by coumarin-3-acyl derivatives: biological activity and computational study. Bioorg. Med. Chem. Lett, 2004, 14, 3697-3703.
40. Fioravanti, R.; Bolasco, A.; Manna, F.; Rossi, F.; Orallo, F.; Yanez, M.; Vitali, A.; Ortuso, F.; Alcaro, S. Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors. Bioorg Med Chem Lett, 2010, 20, (22), 6479-6482.
41. Núñez, M.B.; Maguna, F.P.; Okulika, N.B.; Castro, E.A. QSAR modeling of the MAO inhibitory activity of xanthones derivatives. Bioorg Med Chem Lett, 2004, 14, 5611-5617.
42. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Cirilli, R.; La Torre, F.; Alcaro, S.; Ortuso, F.; Langer, T. Synthesis, biological evaluation and 3DQSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors. Curr Med Chem, 2006, 13, (12), 1411-1428.
43. Chen, S.; Cho, M.; Karlsberg, K.; Zhou, D.; Yuan, Y.C. Biochemical and biological characterization of a novel antiaromatase coumarin derivative. J. Biol. Chem., 2004, 279, (46), 48071-48078.
44. Leonetti, F.; Favia, A.; Rao, A.; Aliano, R.; Paluszcak, A.; Hartmann, R.W.; Carotti, A. Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. J. Med. Chem., 2004, 47, (27), 6792-6803.
45. Bruhlmann, C.; Ooms, F.; Carrupt, P.A.; Testa, B.; Catto, M.; Leonetti, F.; Altomare, C.; Carotti, A. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J. Med. Chem., 2001, 44, (19), 3195-3198.
46. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F. Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of N,N'-bis[2-oxo-2Hbenzopyran]-3-carboxamides Bioorg. Med. Chem. Lett., 2006, 16, 4135-4140.
47. Carotti, A.; Altomare, C.; Catto, M.; Gnerre, C.; Summo, L.; De Marco, A.; Rose, S.; Jenner, P.; Testa, B. Lipophilicity plays a major role in modulating monoamine oxidase B (MAO-B) inhibition by 7-substituted coumarins. Chem. Biodiversity, 2006, 3, 134-144.
48. Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Favia, A.D.; Soto-Otero, R.; Méndez-Alvarez, E.; Carotti, A. Structural insights into monoamine oxidase inhibitory potency and selectivity of 7- substituted coumarins from ligand- and target-based approaches. J. Med. Chem., 2006, 49, 4912-4925.
49. Newton-Vinson, P.; Hubalek, F.; Edmondson, D.E. High-level expression of human liver monoamine oxidase B in Pichia pastoris. Protein Expression Purif., 2000, 20, 334-345.
50. Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D.E.; Mattevi, A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 9750-9755.
51. Upadhyay, A.K.; Wang, J.; Edmondson, D.E. Comparison of the structural properties of the active site cavities of human and rat monoamine oxidase A and B in their soluble and membrane-bound forms. Biochemistry, 2008, 47, 526-536.
52. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D.E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 12684-12689.
53. Hubalek, F.; Binda, C.; Khalil, A.; Li, M.; Mattevi, A.; Castagnoli, N.; Edmondson, D.E. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J. Biol. Chem., 2005, 280, 15761-15766.
54. Novaroli, L.; Daina, A.; Favre, E.; Bravo, J.; Carotti, A.; Leonetti, F.; Catto, M.; Carrupt, P.A.; Reist, M. Impact of species-dependent differences on screening, design, and development of MAO B inhibitors. J. Med. Chem., 2006, 49, (21), 6264-6272.
55. Santana, L.; González-Díaz, H.; Quezada, E.; Uriarte, E.; Yáñez, M.; Viña, D.; Orallo, F. Quantitative Structure-Activity Relationship and Complex Network Approach to Monoamine Oxidase A and B Inhibitors. J. Med. Chem., 2008, 51, 6740-6751.
56. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.; Carradori, S.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. Synthesis, Molecular Modeling, and Selective Inhibitory Activity against Human Monoamine Oxidases of 3-Carboxamido-7-Substituted Coumarins. J. Med. Chem., 2009, 52, 1935-1942.
57. Ishar, M.P.S.; Singh, G.; Singh, S.; Sreenivasan, K.K.; Singh, G. Design, synthesis, and evaluation of novel 6-chloro-/fluorochromone derivatives as potential topoisomerase inhibitor anticancer agents. Bioorg. Med. Chem. Lett., 2006, 16, 1366-1370.
58. Peixoto, F.; Barros, A.I.R.N.A.; Silva, A.M.S. Interactions of a new 2-styrylchromone with mitochondrial oxidative phosphorylation. J. Biochem. Mol. Toxicol., 2002, 16, 220-226.
59. Gaspar, A.; Teixeira, F.; Uriarte, E.; Milhazes, N.; Melo, A.; Cordeiro, M.N.; Ortuso, F.; Alcaro, S.; Borges, F. Towards the discovery of a novel class of monoamine oxidase inhibitors: structure-property-activity and docking studies on chromone amides. ChemMedChem, 2011, 6, (4), 628-632.
60. Gaspar, A.; Silva, T.; yanez, M.; Vina, D.; Orallo, F.; Ortuso, F.; Uriarte, E.; Alcaro, S.; Borges, F.M. Chromone a privileged scaffold for the development of monoamine oxidase inhibitors. J. Med. Chem., 2011, 54, (14), 5165-5173.
61. Gaspar, A.; Reis, J.; Fonseca, A.; Milhazes, N.; Vina, D.; Uriarte, E.; Borges, F. Chromone 3-phenylcarboxamides as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett, 2011, 21, (2), 707-709.
62. Yanez, M.; Fraiz, N.; Cano, E.; Orallo, F. Inhibitory effects of cisand trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem Biophys Res Commun, 2006, 344, (2), 688-695.
63. Go, M.L.; Wu, X.; Liu, X.L. Chalcones: an update on cytotoxic and chemoprotective properties. Curr. Med. Chem., 2005, 12, 481-499.
64. Trivedi, J.C.; Bariwal, J.B.; Upadhyay, K.D.; Naliapara, Y.T.; Soshi, S.K.; Pannecouque, C.C.; De Clercq, E.; Shah, A.K. Improved and rapid synthesis of new coumarinyl chalcone derivatives and their antiviral activity. Tetrahedron Lett., 2007, 48, 8472-8474.
65. Haraguchi, H.; Tanaka, Y.; Kabbash, A.; Fujioka, T.; Ishizu, T.; Yagi, A. Monoamine oxidase inhibitors from Gentiana lutea. Phytochemistry, 2004, 65, 2255-2260.
66. Jamal, H.; Ansari, W.H.; Rizvi, S.J. Evaluation of chalcones-a flavonoid subclass for their anxiolytic effect in rats using elevated plus maze and open field behaviour tests. Fund. Clin. Pharmacol., 2008, 22, 673-681.
67. Tanaka, S.; Kuwai, Y.; Tabata, M. Isolation of Monoamine Oxidase Inhibitors from Glycyrrhiza uralensis Roots and the Structure-Activity Relationship. Planta Med., 1987, 53, 5-8.
68. Petzer, J.P.; Castagnoli, N., Jr.; Schwarzschild, M.A.; Chen, J.F.; Van der Schyf, C.J. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics, 2009, 6, (1), 141-151.
69. Weinreb, O.; Mandel, S.; Bar-Am, O.; Yogev-Falach, M.; Avramovich-Tirosh, Y.; Amit, T.; Youdim, M.B. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics, 2009, 6, (1), 163-174.
70. Silver, H.; Chertkow, Y.; Weinreb, O.; Danovich, L.; Youdim, M. Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia? Neurotherapeutics, 2009, 6, (1), 86-93.
71. Van der Schyf, C.J.; Youdim, M.B. Multifunctional drugs as neurotherapeutics. Neurotherapeutics, 2009, 6, (1), 1-3.
72. Weinreb, O.; Amit, T.; Mandel, S.; Kupershmidt, L.; Youdim, M.B. Neuroprotective multifunctional iron chelators: from redoxsensitive process to novel therapeutic opportunities. Antioxid Redox Signal, 2010, 13, (6), 919-949.
73. Youdim, M.B.; Geldenhuys, W.J.; Van der Schyf, C.J. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease? Parkinsonism Relat Disord, 2007, 13 Suppl 3, S281-S291.
74. Bar-Am, O.; Amit, T.; Youdim, M.B. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem, 2007, 103, (2), 500-508.
75. Youdim, M.B.H.; Buccafusco, J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci., 2005, 26, 27-35.
76. Bar-Am, O.; Amit, T.; Weinreb, O.; Youdim, M.B.; Mandel, S. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. J Alzheimers Dis, 21, (2), 361-371.
77. Bar-Am, O.; Weinreb, O.; Amit, T.; Youdim, M.B. The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. J Mol Neurosci, 2009, 37, (2), 135-145.
78. Caccia, C.; Maj, R.; Calabresi, M.; Maestroni, S.; Faravelli, L.; Curatolo, L.; Salvati, P.; Fariello, R.G. Safinamide: From MolecularTargets to a New Anti-Parkinson Drug. Neurology, 2006, 67, S18-S23.
79. Aguiar, L.M.; Macedo, D.S.; Vasconcelos, S.M.; Oliveira, A.A.; de Sousa, F.C.; Viana, G.S. CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDAlesioned rats. Brain Res, 2008, 1191, 192-199.
80. Frederick, R.; Ooms, F.; Castagnoli, N., Jr.; Petzer, J.P.; Feng, J.F.; Schwarzschild, M.A.; Van der Schyf, C.J.; Wouters, J. (E)-8-(3-Chlorostyryl)-1,3,7-trimethylxanthine, a caffeine derivative acting both as antagonist of adenosine A2A receptors and as inhibitor of MAO-B. Acta Crystallogr C, 2005, 61, (Pt 9), o531-o532.
81. Waters, C. Other pharmacological treatments for motor complications and dyskinesias. Mov Disord, 2005, 20 Suppl 11, S38-S44.
82. Chen, J.F.; Xu, K.; Petzer, J.P.; Staal, R.; Xu, Y.H.; Beilstein, M.; Sonsalla, P.K.; Castagnoli, K.; Castagnoli, N.; Schwarzchild, M.A., 21, Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci., 2001, 21, RC143/141-RC143/146.
83. Vlok, N.; Malan, S.F.; Castagnoli, N., Jr.; Bergh, J.J.; Petzer, J.P. Inhibition of monoamine oxidase B by analogs of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC). Bioorg Med Chem, 2006, 14, (10), 3512-3521.
84. Pretorius, J.; Malan, S.F.; Castagnoli, N., Jr.; Bergh, J.J.; Petzer, J.P. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1- yl)caffeine analogs. Bioorg Med Chem, 2008, 16, (18), 8676-8684.